Kintara Therapeutics (KTRA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kintara Therapeutics is set to merge with TuHURA Biosciences, aiming to close the deal on October 18, 2024, and has announced the issuance of Contingent Value Rights to its shareholders on the eve of the merger. Stockholders as of October 17, 2024, will receive CVRs entitling them to shares of Kintara’s common stock, which may be adjusted based on certain milestones and the upcoming reverse stock split. This strategic step is expected to enhance Kintara’s portfolio with TuHURA’s advanced immune-oncology technologies.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
